Benitec Biopharma Inc
Veridion Score
Composite trend over time
Why is BNTC moving today?
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BNTC.
BNTC insider activity
Benitec Biopharma Inc
No multi-insider buying cluster in the last 90 days
Net buying: $22.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Insider | buy | $13.44 | 11,587 | 1,848,156 | $156K | SEC Form 4 |
| 2025-12-29 | 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Insider | buy | $13.44 | 65,800 | 9,700,195 | $884K | SEC Form 4 |
| 2025-12-29 | 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Insider | buy | $13.10 | 2,516 | 1,836,569 | $33K | SEC Form 4 |
| 2025-12-29 | 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Insider | buy | $13.10 | 14,320 | 9,634,395 | $188K | SEC Form 4 |
| 2025-12-29 | 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Insider | buy | $12.85 | 7,400 | 1,834,053 | $95K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 9 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBNTC contract awards, year to date.
Public federal awards linked to this ticker.
BNTC lobbying filings, year to date.
Registered lobbying filings matched to Benitec Biopharma Inc.